Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Bone Density Conservation Agents

Antineoplastic Agents

All Drugs and Chemicals

Pharmaceutical Solutions

Reproductive Control Agents

Central Nervous System Stimulants

Tamoxifen

Hormones

Fulvestrant

Exemestane

Letrozole

Megestrol

Megestrol Acetate

Anastrozole

Aromatase Inhibitors

Enzyme Inhibitors

Estrogens

Estrogen Antagonists

Estrogen Receptor Antagonists

Hormone Antagonists

Antineoplastic Agents, Hormonal

Estrogen Receptor Modulators

Selective Estrogen Receptor Modulators

Contraceptive Agents

Contraceptives, Oral

Contraceptives, Oral, Hormonal

Contraceptive Agents, Female

Contraceptive Agents, Hormonal

Megestrol acetate 160 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.

Anastrozole 1 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.

Letrozole 2.5 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.

Exemestane 25 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.

Tamoxifen 20 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.

Fulvestrant 500 mg intramuscularly (IM) d1, d14, d28 and q28 days until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.

Megestrol Acetate 160Mg Tablet

Anastrozole 1Mg Tablet

Letrozole 2.5Mg Tablet

Exemestane 25 MG

Tamoxifen 20Mg Tablet

Fulvestrant 500 mg IM d1, d14, d28 and q28 days

Fulvestrant 50Mg Solution for Injection

Renata Obadia, RN

José Bines, MD, PhD

Jason Carroll, PhD

This pilot trial evaluates in vivo megestrol acetate (MA) modulation of steroidal receptors in advanced breast cancer.

Progesterone receptor (PR) expression has been considered a biomarker of oestrogen receptor-α (ERα) activity. This longstanding relationship has been recently challenged and instead of being merely an ERα-induced gene target, PR may be a critical determinant of ERα activity. The functional significance of this steroid receptor crosstalk is regulation of a gene expression program associated with low tumorigenicity; hence, better disease outcome. Genomic alterations in the PR genomic locus seem to be a relatively common mechanism for reduction of PR expression, which may consequently lead to altered ERα chromatin binding and target gene expression patterns that increase breast tumorigenicity and confers a poor clinical outcome. This ERα-PR crosstalk may be directly influenced by many variables, including the relative receptor levels and the hormonal milieu.

ER-positive advanced breast cancer is a heterogeneous group of diseases with considerable variability in outcome to a range of treatments. Prior response predicts the likelihood of subsequent benefit from another endocrine agent and this should be taken into account in the treatment decision process when assessing whether to prescribe a subsequent endocrine therapy. Despite the enormous progress made regarding the elucidation of breast cancer subgroups and their molecular drivers, most information comes from primary tumors. MA lacks cross-resistance and is active after acquired resistance to potent AI. This pilot trial evaluates in vivo MA modulation of steroidal receptors in advanced breast cancer.

A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer

A Pilot Study Evaluating Megestrol Acetate Modulation in Advanced Breast Cancer With Positive Hormonal Receptor

From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months

From date of randomization until the date of death from any cause, assessed up to 18 months

Partial response and stable disease for more than 24 weeks, as per RECIST criteria, from date of randomization until the date of first documented progression or date of death, whichever came first, assessed up to 18 months

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	NCT03024580	Breast Neoplasm	Megestrol Aceta... Anastrozole 1Mg... Letrozole 2.5Mg... Exemestane 25 M... Tamoxifen 20Mg ... Fulvestrant 50M...	-	Instituto Nacional de Cancer, Brazil
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	NCT03024580	Breast Neoplasm	Megestrol Aceta... Anastrozole 1Mg... Letrozole 2.5Mg... Exemestane 25 M... Tamoxifen 20Mg ... Fulvestrant 50M...	-	Instituto Nacional de Cancer, Brazil
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	NCT03024580	Breast Neoplasm	Megestrol Aceta... Anastrozole 1Mg... Letrozole 2.5Mg... Exemestane 25 M... Tamoxifen 20Mg ... Fulvestrant 50M...	-	Instituto Nacional de Cancer, Brazil

Spots Global Cancer Trial Database for fulvestrant 50mg solution for injection